Comparative pharmacokinetics study of two different clindamycin capsule formulations: A randomized, two-period, two-sequence, two-way crossover clinical trial in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 9, 2011, Pages 538-543

  Sanki, Utpal Kumar ^a   Mandal, Badal Kumar ^a   Chandrakala, Venkatesh ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Bioequivalence; Clindamycin; Macrolide antibiotic; Pharmacokinetics

Indexed keywords

CAS 21462395; CLINDAMYCIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 80053387533     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296241     Document Type: Article

References (27)

1. Birkenmeyer RD, Kagan F. Lincomycin. XI: Synthesis and structure of clindamycin, a potent antibacterial agent. J Med Chem. 1970;13:616-9.
2. Holly A. Stevens MD. Clindamycin. Prime Care Update Ob/ Gyns. 1997;4(6):251-3.
3. Klepser ME, Nicolau DP, Quintiliani R, Nightingale CH. Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1997;41:630-5. (Pubitemid 27098416)
4. Lewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrob Agents Chemother. 1999;43:2005-9. (Pubitemid 29395200)
5. Xue IB, Davey PG, Phillips G. Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. Antimicrob Agents Chemother.1996;40:1403-7. (Pubitemid 26169050)
6. Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, blactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother. 2004;53:609-15. (Pubitemid 38499775)
7. Xue, Davey IBPG, Phillips G. Variation in the postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. Antimicrob Agents Chemother. 1996;40:1403-7.
8. Ameer BA, Sesin P, Karchmer AW. Selecting clindamycin dosing regimens. AmJ Hosp Pharm. 1987;44:2027-8.
9. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993;37:1137-43. (Pubitemid 23141333)
10. DeHaan RM, Metzler CM, Schellenberg D, vanden Bosch WD, Masson EL. Pharmacokinetic studies of clindamycin hydrochloride in humans. Int J Clin Pharmacol. 1972;6: 105-19.
11. Levinson RS, Mitan SJ, Steinmetz JI, Gattermeir DJ, Schumacher RJ, Joffrion JL. An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations. Clin Ther. 2005:12;1894-900. (Pubitemid 43293211)
12. Sun F. Disposition of clindamycin in rat and dog. Fed Proc AmSoc Exp Biol. 1970;29:677-82.
13. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab. Dispos. 2003;31: 878-87. (Pubitemid 36759057)
14. Sun FF, Metabolism of clindamycin. II: Urinary excretion products of clindamycin in rat and dog. J PharmSci. 1973; 62:1657-62.
15. Gatti G, Malena M, Casazza R, Borin M, Bassetti M, Cruciani M. Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphatein patients with AIDS. Antimicrob Agents Chemother. 1998;42:3014-17. (Pubitemid 28501245)
16. Klepser ME, Banevicius MA, Quintiliani R, Nightingale CH. Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother. 1996;40:1941-4. (Pubitemid 26277822)
17. Gray JE, Weaver RN, Bollert JA, Feenstra ES. The Oral Toxicity of Clindamycin in Laboratory Animals. Toxicol Appl Pharmacol. 1972;21;516-31.
18. Stevens H. Prim Care Update Ob/Gyns. 1997;4:251-3.
19. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, International Conference on Harmonisation. Guideline for Good Clinical Practice [EMEA web site, accessed March 26, 2007.]. http:// www.emea.eu.int
20. FDA Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. Rockville, MD: Office of Generic Drugs, Division of Bioequivalence, US Food and Drug Administration; 2003.
21. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations [US Food and Drug Administration (FDA) web site, accessed March 18, 2007]. http://www.fda.gov/ cder/guidance/S356fnl.pdf
22. Fieger-Buschges H, Schubler G, Larsimont V, Blume H. Determination of clindamycin in human plasma by high-performance liquid chromatography using coupled columns. J Chromatog. 1999;724:281-6. (Pubitemid 29148088)
23. Shumaker RC. PK Calc: a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17:331-48.
24. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 1987;6:539-46.
25. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York, NY: Marcel Dekker Inc; 1992.
26. Swartzberg JE, Maresca RM, Remington JS. Gastrointestinal side effects associated with clindamycin. Arch Intern Med. 1976;136:876-9.
27. CPMP (Committee for Proprietary Medicinal Products), Note for Guidance on the Investigation of Bioavailability and Bioequivalence; 2001.